title: Acute effect of endothelin-1 on lung oedema induced by alpha-naphthylthiourea (ANTU).
abstract: Alpha-naphthylthiourea when injected intraperitoneally to rats (10 mg kg-1 i.p.) produced lung oedema as indicated by an increase in lung weight/body ratio and pleural effusion reaching a maximum within 4 hours. Prior intravenous single bolus injection of endothelin-1 elicited a significant and dose-dependent inhibition in both parameters. However, prior i.v. injection of angiotensin II using relatively higher doses did not alter the oedema-producing effect of alpha-naphthylthiourea indicating a characteristic for endothelin-1. The inhibitory effect of endothelin-1 on pleural effusion is more prominent than lung weight/body weight ratio. The resolution of lung oedema by single bolus i.v. injection of endothelin-1 is probably due to the acute long-lasting and potent vasoconstrictor effect of the peptide and its large accumulation in lung tissue. Phosphoramidon, an inhibitor of endothelin converting enzyme, did not alter the oedema producing effect of alpha-naphthylthiourea indicating the lack of the participation of endothelin-peptide cascade to this pathological event. Bosentan, a non-selective receptor blocker of endothelin-1, did not inhibit the preventive effect of the peptide against alpha-naphthylthiourea-induced lung oedema. Possible mechanisms of the acute effect of endothelin-1 on lung oedema are discussed.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Gazi University, Ankara, Turkey.
authors.forename: E
authors.initials: E
authors.lastname: Sipahi
authors.forename: U
authors.initials: U
authors.lastname: Hodoglugil
authors.forename: Z S
authors.initials: ZS
authors.lastname: Ercan
authors.forename: R K
authors.initials: RK
authors.lastname: Türker
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D001835:Body Weight / Q000187:drug effects; D000077300:Bosentan; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000072396:Endothelin-Converting Enzymes; D006020:Glycopeptides / Q000494:pharmacology; D008297:Male; D008666:Metalloendopeptidases; D009929:Organ Size / Q000187:drug effects; D010996:Pleural Effusion / Q000188:drug therapy; D011480:Protease Inhibitors / Q000494:pharmacology; D011654:Pulmonary Edema / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology; D013890:Thiourea / Q000031:analogs & derivatives*
chemical_list: D019332:Endothelin-1; D006020:Glycopeptides; D011480:Protease Inhibitors; D013449:Sulfonamides; D000804:Angiotensin II; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes; D013890:Thiourea; D000077300:Bosentan; C008890:phosphoramidon; C005277:alpha-naphthyl thiourea